Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilzemetkib in Advanced Lung and Ovarian Cancer
NCT05815862Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vilzemetkib in lung cancer, ovarian cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Feb 2023; status: completed.
02
Drugs
vilzemetkib
03
Conditions
lung cancerovarian cancer
Beyond the preview
Go deeper on NCT05815862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05815862.